BDMD Baird Medical Investment Holdings Limited
USHealthcareAs of 2026-07-10 16:00
Why BDMD matters now
Baird Medical Investment Holdings Limited (BDMD) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.13 with -0.88% on the session and $46.3M in market capitalization; recent performance reads 1-month -32.32% and YTD -18.38%.
The latest financial table shown here is Q4 2025, with revenue of $14.6M, net income of $-16.0M, and EPS of $-0.55. Investors can compare that operating picture with valuation signals such as P/E 6.93 and FCF yield -3.0%.
The latest indexable market news headline is "Baird Medical Announces First Microwave Ablation Procedures Using Its Technology in Vietnam and Argentina" from PRNewsWire.
Additional event context on this page matters because recent insider activity includes Lu Rongjian filing . These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
6.93
PEG
—
P/B
1.02
P/S
2.02
EV/EBITDA
-2.67
DCF Value
$2.65
FCF Yield
-3.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
83.8%
Operating Margin
-113.7%
Net Margin
-121.0%
ROE
-81.5%
ROA
-39.1%
ROIC
-50.7%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $14.6M | $-16.0M | $-0.55 |
| FY 2025 | $22.5M | $-27.3M | $-0.98 |
| Q2 2025 | $8.0M | $-11.3M | $-0.43 |
| Q4 2024 | $23.9M | $8.1M | $0.38 |
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
CN
Exchange
—
Beta
-1.23
Based in China, Baird Medical Investment Holdings Limited and its associated entities specialize in engineering and commercializing microwave ablation medical apparatus. These sophisticated instruments are employed in the minimally invasive management of a diverse array of benign and malignant tumors, notably targeting thyroid nodules, hepatic carcinomas, pulmonary cancers, and mammary lesions. The organization was established in 2012, with its corporate headquarters situated in Guangzhou, China.